Building a benefits strategy that survives the next medical breakthrough

Direct primary care and concierge medicine sit on the other side of that ledger. They are not flashy and are rarely framed as disruption, but they are exactly the kind of durable, compounding asset that can give you an innovation ready chassis instead of a benefits strategy that has to be rebuilt every time the headlines change.

Seeing gene therapy in perspective

Gene therapy belongs in the employer risk conversation, just not at the center of the benefits philosophy. It is rare but severe, which makes it emotionally salient and actuarially spiky. A small number of cases can produce seven figure claims that hit stop loss, reserves, and board reporting in a single year. That deserves attention and a clear financing strategy.

It does not, however, justify reorganizing an entire health plan around an event that almost none of the covered population will ever experience. Most health care dollars are still consumed by diabetes, hypertension, musculoskeletal issues, mental health conditions, maternity, and a handful of other chronic or recurring needs. Those are not addressed by the latest gene therapy carve out. They are addressed by access, continuity, and trust at the front door of the health system.

When organizations over rotate to the rare but dramatic, they under invest in the common but compounding.

A more useful framing is the risk pyramid. If you sketched health spend as a pyramid, most dollars would sit in the wide base of everyday and chronic care, with only a narrow tip reserved for rare, catastrophic interventions. At the base is routine and preventive care. Above that are chronic disease and moderate acuity events that can escalate if poorly managed. Near the top are catastrophic or curative interventions such as advanced oncology, transplants, and cell and gene therapies. Each layer calls for a different tool. Confusing the layers leads to overbuying at the top and underbuilding at the base.

Strategy instead of product reaction

Most employers do not need another product as much as they need a repeatable way to evaluate every new medical innovation that hits the market. Without that, the benefits plan becomes a scrapbook of vendor pitches and historical decisions rather than a coherent strategy.

A practical framework can start with four questions:

• Frequency and severity. Is this a high frequency, moderate cost issue like primary care and chronic disease management, or a low frequency, high-cost event like gene therapy or complex transplant care?
• Location in the care journey. Does this innovation operate upstream (prevention, primary care), midstream (disease management, behavioral health), or downstream (rescue and curative therapies)?
• Specific problem solved. Does it reduce volatility, improve predictability, address a known access gap, or support talent strategy, or is it primarily a response to external noise?
• Operational complexity introduced. How many new contracts, data feeds, member touchpoints, and internal governance requirements does it add?

If an innovation does not have clear answers on the first two questions, does not map to a known gap in the existing care journey, and adds complexity without an obvious strategic benefit, it should face a high bar for adoption. Conversely, if it measurably reduces the cost and friction of common events or protects against tail risk, it deserves serious consideration.

This framework shifts the conversation from "Should we buy this gene therapy solution" to "Where does this category sit in our overall risk portfolio, and how will we manage that layer over the next decade."

Building an innovation-ready chassis

Once leaders think in terms of layers, they can design a benefits structure that absorbs new shocks without a full rebuild.

At the catastrophic end, enhanced stop loss, reinsurance pools, captives, and performance-based arrangements with centers of excellence are the right tools. These are classic risk transfer and risk sharing mechanisms, and they will continue to evolve as new therapies come to market.

At the base and middle of the pyramid, organizations need something more fundamental: a stable, consistent way for employees to access relationship based primary care. That is where direct primary care and concierge medicine come in. They do not change every time a new drug class is approved. They are a consistent operating system for how employees enter and move through the health system.

Across different markets, I have seen DPC and concierge models work well when the benefits are layered: predictable subscription style costs covering a large portion of routine and chronic care; faster access and longer visits that reduce unnecessary specialist referrals and emergency department use; a trusted clinician who can coordinate care when high cost events do occur, including evaluation and follow up for gene or cell therapies; and better information inside the care relationship, which improves the ability to evaluate other innovations and hold vendors accountable.

In economic terms, DPC and concierge create a more stable middle of the distribution. When everyday spend is more predictable and well managed, tail events remain important but no longer threaten to distort the entire budget philosophy.

A quieter, more durable path to resilience

It is tempting to treat benefits innovation like a technology cycle, with a constant next big thing and a steady stream of compelling pitches. For most employers, however, the goal is not to be first with every innovation. The goal is to be deliberate about the ones that matter most to their people and their balance sheet.

That often means letting some solutions mature, watching outcomes and contractual performance, and entering when data and terms are more favorable. That is not timidity. It is governance.

At the same time, there is a real opportunity to build a front door that actually works. To push as much care as possible into consistent, relationship-based settings, and to give employees a known place to go when they are worried, not only when they are already in crisis. To align plan design and contributions so that primary care is easy to use, not something people feel they should avoid. In that context, DPC and concierge are not perks. They are core infrastructure.

The payoff is not a single year of savings. It is a decade of fewer avoidable admissions, better managed chronic disease, more stable stop loss negotiations, and a workforce that does not experience the health plan as a maze of disconnected programs.

When the next breakthrough therapy arrives, and the next wave of carve outs and risk pools appears with it, employers can evaluate them against a clear strategy and a solid base rather than out of fear that failing to react will leave them behind. That is what an innovation ready benefits strategy looks like.

Where to start

For CHROs and CFOs ready to move from product reaction to strategy, the first step is not adding another solution. It is mapping the organization's own risk pyramid: how much spend lives in primary and preventive care, chronic disease, moderate acuity, and catastrophic events, and how many vendors and programs currently touch each layer.

From there, two questions can guide the next phase. First, what would it look like to simplify the front door of care for employees, and could direct primary care or concierge contracting be part of that? Second, how will the organization decide which future innovations deserve a place in the plan, and what criteria will be applied consistently before adding more complexity?

Gene therapies and other breakthroughs will keep coming. The challenge is not to predict which one will matter most. The challenge is to ensure that when they arrive, they land on an architecture built for turbulence, not a patchwork of past reactions.